Rhythm Pharmaceuticals, Inc. (RYTM)
113.44
+2.00
(+1.79%)
USD |
NASDAQ |
Aug 25, 11:04
Rhythm Pharmaceuticals Enterprise Value : 7.562B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 7.562B |
| August 21, 2026 | 7.463B |
| August 20, 2026 | 7.389B |
| August 19, 2026 | 7.857B |
| August 18, 2026 | 7.824B |
| August 17, 2026 | 7.837B |
| August 14, 2026 | 7.840B |
| August 13, 2026 | 7.877B |
| August 12, 2026 | 7.986B |
| August 11, 2026 | 7.659B |
| August 10, 2026 | 7.840B |
| August 07, 2026 | 7.851B |
| August 06, 2026 | 7.608B |
| August 05, 2026 | 7.512B |
| August 04, 2026 | 7.173B |
| August 03, 2026 | 6.966B |
| July 31, 2026 | 6.723B |
| July 30, 2026 | 7.170B |
| July 29, 2026 | 7.224B |
| July 28, 2026 | 7.328B |
| July 27, 2026 | 7.197B |
| July 24, 2026 | 6.919B |
| July 23, 2026 | 6.958B |
| July 22, 2026 | 7.048B |
| July 21, 2026 | 7.229B |
| Date | Value |
|---|---|
| July 20, 2026 | 7.091B |
| July 17, 2026 | 7.229B |
| July 16, 2026 | 7.194B |
| July 15, 2026 | 7.442B |
| July 14, 2026 | 7.460B |
| July 13, 2026 | 7.290B |
| July 10, 2026 | 7.353B |
| July 09, 2026 | 7.840B |
| July 08, 2026 | 7.768B |
| July 07, 2026 | 7.770B |
| July 06, 2026 | 7.579B |
| July 02, 2026 | 7.750B |
| July 01, 2026 | 7.491B |
| June 30, 2026 | 7.534B |
| June 29, 2026 | 7.418B |
| June 26, 2026 | 7.404B |
| June 25, 2026 | 7.296B |
| June 24, 2026 | 7.248B |
| June 23, 2026 | 7.155B |
| June 22, 2026 | 6.826B |
| June 18, 2026 | 6.511B |
| June 17, 2026 | 6.445B |
| June 16, 2026 | 6.027B |
| June 15, 2026 | 6.026B |
| June 12, 2026 | 5.936B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Aprea Therapeutics, Inc. | -30.53M |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.30M |
| Revenue (Quarterly) | 71.26M |
| Total Expenses (Quarterly) | 120.55M |
| EPS Diluted (Quarterly) | -0.7342 |
| Gross Profit Margin (Quarterly) | 87.39% |
| Profit Margin (Quarterly) | -69.19% |
| Earnings Yield | -2.75% |
| Normalized Earnings Yield | -2.739 |